Comparative study of outcomes following laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy in morbidly obese patients: A case control study

Table 3 Impact of bariatric surgery on medications for various comorbidities (n = 80)

Medications	LRYGB		LSG		P value1
	Preoperative period	Postoperative period	Preoperative	Postoperative period
Number of OHA	2.17 ± 0.7	0.3 ± 0.5	1.8 ± 0.7	0.3 ± 0.6	0.73
Number of AHA	1.7 ± 0.7	0.5 ± 0.5	1.7 ± 0.8	0.6 ± 0.6	0.78
Dosage of thyroxine (μg/d)	90.9 ± 25.7	45.5 ± 40.1	89.3 ± 31.8	53.6 ± 39.3	0.33

All data expressed as mean ± SD.

¹All P values were calculated using Student’s t test separately for all comorbidities. AHA: Anti-hypertensive agents; OHA: Oral hypoglycemic agents; LRYGB: Laparoscopic Roux-en-Y gastric bypass; LSG: Laparoscopic sleeve gastrectomy.